MA45168A - Peptidomimétique en épingle à cheveux bêta ayant une activité inhibitrice à l'encontre de l'élastase, et ses formes posologiques en aérosol - Google Patents

Peptidomimétique en épingle à cheveux bêta ayant une activité inhibitrice à l'encontre de l'élastase, et ses formes posologiques en aérosol

Info

Publication number
MA45168A
MA45168A MA045168A MA45168A MA45168A MA 45168 A MA45168 A MA 45168A MA 045168 A MA045168 A MA 045168A MA 45168 A MA45168 A MA 45168A MA 45168 A MA45168 A MA 45168A
Authority
MA
Morocco
Prior art keywords
inhibitoring
peptidomimetic
elastase
activity
dosage forms
Prior art date
Application number
MA045168A
Other languages
English (en)
Inventor
Philip Barth
Piet Bruijnzeel
Eric Chevalier
Manfred Keller
Christian Ludin
Johann Zimmermann
Original Assignee
Polyphor Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polyphor Ag filed Critical Polyphor Ag
Publication of MA45168A publication Critical patent/MA45168A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
MA045168A 2016-05-31 2017-05-31 Peptidomimétique en épingle à cheveux bêta ayant une activité inhibitrice à l'encontre de l'élastase, et ses formes posologiques en aérosol MA45168A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16020210 2016-05-31

Publications (1)

Publication Number Publication Date
MA45168A true MA45168A (fr) 2019-04-10

Family

ID=56108445

Family Applications (2)

Application Number Title Priority Date Filing Date
MA045168A MA45168A (fr) 2016-05-31 2017-05-31 Peptidomimétique en épingle à cheveux bêta ayant une activité inhibitrice à l'encontre de l'élastase, et ses formes posologiques en aérosol
MA045167A MA45167A (fr) 2016-05-31 2017-05-31 Peptidomimétique en épingle à cheveux bêta présentant une activité d'inhibition de l'élastase et formes pharmaceutiques aérosols correspondantes

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA045167A MA45167A (fr) 2016-05-31 2017-05-31 Peptidomimétique en épingle à cheveux bêta présentant une activité d'inhibition de l'élastase et formes pharmaceutiques aérosols correspondantes

Country Status (27)

Country Link
US (3) US11235024B2 (fr)
EP (2) EP3463280B1 (fr)
JP (4) JP7544466B2 (fr)
KR (2) KR102511284B1 (fr)
CN (3) CN109195580A (fr)
AU (2) AU2017273508B2 (fr)
BR (2) BR112018074551B1 (fr)
CA (2) CA3024522C (fr)
CL (2) CL2018003390A1 (fr)
DK (2) DK3463280T3 (fr)
EA (2) EA039603B1 (fr)
ES (2) ES2927948T3 (fr)
HR (2) HRP20221194T1 (fr)
HU (2) HUE060119T2 (fr)
IL (2) IL263114B2 (fr)
LT (2) LT3463281T (fr)
MA (2) MA45168A (fr)
MX (2) MX2018014425A (fr)
PH (2) PH12018502521A1 (fr)
PL (2) PL3463280T3 (fr)
PT (2) PT3463281T (fr)
RS (2) RS63639B1 (fr)
SG (3) SG10202113280XA (fr)
SM (2) SMT202200404T1 (fr)
UA (2) UA125900C2 (fr)
WO (2) WO2017207117A1 (fr)
ZA (2) ZA201807772B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE060119T2 (hu) * 2016-05-31 2023-02-28 Spexis Ag Béta-hairpin peptidomimetikum elasztáz gátló hatással és annak aeroszolos adagolási formái
CA3151997A1 (fr) * 2019-08-23 2021-03-04 Ph Pharma Co., Ltd. Utilisation d'un inhibiteur de l'elastase neutrophile dans les maladies pulmonaires
KR20220133227A (ko) * 2020-01-30 2022-10-04 버텍스 파마슈티칼스 인코포레이티드 알파-1 항트립신 결핍증의 치료 방법
CN115697969B (zh) 2020-04-03 2026-08-11 弗特克斯药品有限公司 α-1抗胰蛋白酶调节剂
AU2021247285A1 (en) 2020-04-03 2022-10-27 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
JP7732999B2 (ja) 2020-04-03 2025-09-02 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ１－アンチトリプシンのモジュレーター
EP4188931A2 (fr) 2020-07-27 2023-06-07 Vertex Pharmaceuticals Incorporated Procédés de préparation de modulateurs de l'alpha-1 antitrypsine
KR20230123950A (ko) * 2020-11-23 2023-08-24 스펙시스 아게 베타-헤어핀 펩티도미메틱의 조성물 및 이의 에어로졸 투여 형태
CN116782879A (zh) * 2020-11-23 2023-09-19 斯佩希斯股份公司 β-发夹素拟肽的组合物及其气雾剂剂型
CN116421704A (zh) * 2023-02-20 2023-07-14 成都佩德生物医药有限公司 多肽pd-dp-005在制备治疗肺部疾病药物中的应用及其药物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1304118A3 (fr) * 1996-11-01 2004-01-14 XOMA Technology Ltd. Emplois thérapeutiques des produits de la protéine BPI
AU2006206272A1 (en) 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion
EP1856140B1 (fr) * 2005-02-17 2013-12-25 Polyphor Ltd. Peptidomimetiques en epingle a cheveux beta fixes sur matrice, ayant une activite inhibitrice des proteases
EP1712220A1 (fr) * 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Composition d'aérosol pharmaceutique
RU2433841C2 (ru) * 2006-02-09 2011-11-20 Пари Фарма Гмбх Доставка в легкие альфа-1-ингибитора протеиназ
JP2009526003A (ja) * 2006-02-10 2009-07-16 パーリ・ファルマ・ゲーエムベーハー 吸入療法用噴霧状抗生物質
WO2008025560A1 (fr) * 2006-09-01 2008-03-06 Pari Pharma Gmbh Procédés servant à masquer le goût de compositions nébulisées pour thérapie par inhalation nasale et pulmonaire
EP1927373B1 (fr) * 2006-11-30 2012-08-22 PARI Pharma GmbH Nebuliseur d'inhalation
EP2567691B1 (fr) * 2011-09-12 2014-12-24 Meiji Seika Pharma Co., Ltd. Compositions aqueuses comportant de l'arbékacine
US9453829B2 (en) 2013-12-23 2016-09-27 Shijiazhuang Tiedao University Soil property test device
US10340848B2 (en) 2013-12-26 2019-07-02 Kaneka Corporation I-V measurement device for solar cell, manufacturing method for solar cell, and solar cell module
LT3087094T (lt) 2013-12-27 2022-09-26 Spexis Ag Beta plaukų segtuko struktūros peptidų mimetikai, kaip selektyvūs elastazės slopikliai
JP6499182B2 (ja) * 2013-12-27 2019-04-10 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ 選択的エラスターゼ阻害剤としてのβ−ヘアピンペプチド模倣体
HUE060119T2 (hu) * 2016-05-31 2023-02-28 Spexis Ag Béta-hairpin peptidomimetikum elasztáz gátló hatással és annak aeroszolos adagolási formái

Also Published As

Publication number Publication date
US20220023379A1 (en) 2022-01-27
UA125899C2 (uk) 2022-07-06
SMT202200404T1 (it) 2022-11-18
ZA201807772B (en) 2022-10-26
ZA201807773B (en) 2022-07-27
CA3024522C (fr) 2024-06-25
RS63622B1 (sr) 2022-10-31
AU2017273507B2 (en) 2022-03-17
JP7286319B6 (ja) 2023-06-16
CN109195580A (zh) 2019-01-11
LT3463280T (lt) 2022-09-26
DK3463281T3 (da) 2022-09-26
UA125900C2 (uk) 2022-07-06
IL263114A (en) 2018-12-31
PL3463280T3 (pl) 2022-11-07
HRP20221194T1 (hr) 2022-12-09
LT3463281T (lt) 2022-09-26
IL263112B1 (en) 2023-06-01
PT3463281T (pt) 2022-10-07
ES2927948T3 (es) 2022-11-14
CA3024521A1 (fr) 2017-12-07
MX2018014752A (es) 2019-04-25
MA45167A (fr) 2019-04-10
EP3463281B1 (fr) 2022-07-06
IL263114B1 (en) 2023-08-01
US11235023B2 (en) 2022-02-01
MX2018014425A (es) 2019-03-28
JP2022078013A (ja) 2022-05-24
IL263112B2 (en) 2023-10-01
RS63639B1 (sr) 2022-10-31
EP3463281A1 (fr) 2019-04-10
PL3463281T3 (pl) 2022-11-07
KR20190011750A (ko) 2019-02-07
WO2017207118A1 (fr) 2017-12-07
JP7286319B2 (ja) 2023-06-05
JP7544466B2 (ja) 2024-09-03
KR20190015309A (ko) 2019-02-13
ES2928050T3 (es) 2022-11-15
AU2017273508A1 (en) 2018-12-13
CN116159024A (zh) 2023-05-26
CA3024521C (fr) 2023-06-20
BR112018074532A2 (pt) 2019-03-19
PT3463280T (pt) 2022-10-07
CN109310613A (zh) 2019-02-05
JP2023017793A (ja) 2023-02-07
PH12018502522A1 (en) 2019-10-21
EA039603B1 (ru) 2022-02-16
EP3463280B1 (fr) 2022-07-06
HUE060119T2 (hu) 2023-02-28
SG11201810138XA (en) 2018-12-28
US11844823B2 (en) 2023-12-19
DK3463280T3 (da) 2022-09-26
EA201892819A1 (ru) 2019-05-31
BR112018074551B1 (pt) 2022-02-08
JP2019523222A (ja) 2019-08-22
PH12018502521A1 (en) 2019-10-21
KR102480800B1 (ko) 2022-12-22
SG10202113280XA (en) 2021-12-30
EA201892818A1 (ru) 2019-05-31
MX393629B (es) 2025-03-24
IL263114B2 (en) 2023-12-01
IL263112A (en) 2018-12-31
KR102511284B1 (ko) 2023-03-16
AU2017273507A1 (en) 2018-12-13
US20200230203A1 (en) 2020-07-23
HRP20221185T1 (hr) 2022-12-09
US20200230202A1 (en) 2020-07-23
WO2017207117A1 (fr) 2017-12-07
SG11201810137UA (en) 2018-12-28
US11235024B2 (en) 2022-02-01
CA3024522A1 (fr) 2017-12-07
BR112018074551A2 (pt) 2019-03-06
AU2017273508B2 (en) 2022-07-28
BR112018074532B1 (pt) 2022-02-08
EP3463280A1 (fr) 2019-04-10
CL2018003391A1 (es) 2019-05-03
HUE060393T2 (hu) 2023-02-28
SMT202200405T1 (it) 2022-11-18
CL2018003390A1 (es) 2019-05-03
JP2019523763A (ja) 2019-08-29

Similar Documents

Publication Publication Date Title
MA45167A (fr) Peptidomimétique en épingle à cheveux bêta présentant une activité d'inhibition de l'élastase et formes pharmaceutiques aérosols correspondantes
PL3505535T3 (pl) Przeciwciało monoklonalne anty-pd1, jego kompozycja farmaceutyczna i jego zastosowanie
EP3362060A4 (fr) Biomarqueurs associés au diabète et de traitement d'affections associées au diabète
EP4043463C0 (fr) Dérivé à cycle condensé ayant une activité inhibitrice de mgat2
BRPI0815578A2 (pt) Peptídeo de cdca1 e agente farmacêutico compreendendo o mesmo.
BR112017028486A2 (pt) instrumento para higiene bucal e cerdas de monofilamento para uso com o mesmo
EP3399033A4 (fr) Marqueur peptidique et protéine marquée comprenant celui-ci
HUE052837T2 (hu) Lizoszóma-tárolási betegségre irányuló gyógyászati készítmények és alkalmazásaik
EP3318265A4 (fr) Peptide à activité antivirale et composition comprenant ce dernier
PL3636774T3 (pl) Sposób wykrywania chorób wywołanych C. perfringens u zwierząt
EP3452040A4 (fr) Formulations et traitements ayant recours à des hydroxypyridonates décorporants d'actinide/lanthanide
EP3444263A4 (fr) Peptide présentant une activité anti-inflammatoire et utilisation correspondante
IL279877A (en) Ivosidenib forms and pharmaceutical compositions
EP3520651A4 (fr) Poils de brosse à dents en polycétone, et brosse à dents les comprenant
EP3539978A4 (fr) Fragment de nkx3.2 et composition pharmaceutique le comprenant en tant que principe actif
IL283619A (en) Compounds with pde9a prophylactic activity, and their medicinal use
EP3449524A4 (fr) Électrolyte comprenant des dinitriles et des fluoroéthers cycliques
IL283620A (en) Compounds with pde9a prophylactic activity, and their medicinal uses
ITUA20161610A1 (it) Composto peptidico farmacologicamente attivo, procedimento per la sua preparazione e suo uso.
MA52869A (fr) Peptides ayant une activité inhibitrice sur l'exocytose neuronale
EP3534967A4 (fr) Dosage d'activité de protéine d'escorte de rab
HRP20190381T1 (hr) Herbicidni pripravci koji sadrže izoksaflutol i diflufenikan kao jedine herbicidno aktivne sastojke
EP3315128A4 (fr) Régime de dosage d'agent thérapeutique contre l'ataxie associée à la dégénérescence spino-cérébelleuse
Griffis Corea, without and within
杨春芝 On The Translation of Chinese Culture-loaded Words in Chinese American Literature